IKS margin slips sequentially despite 20.74% revenue growth
Costs grew faster than revenue in Q1FY27, while lower interest costs partly offset a 4.22-point rise in the tax rate.
Filed 05 Aug 2026, 21:57 IST · after market close · Inventurus Knowledge Solutions Ltd (IKS)
Key takeaways
- Consolidated revenue grew 20.74% year on year, while operating profit rose 24.05% as costs grew more slowly than revenue.
- Sequential momentum weakened as expenses rose 7.40% against 4.20% revenue growth, narrowing operating margin by 2.01 percentage points.
- Net profit rose 27.85% year on year to Rs 193.74 cr, with only 0.16% of pre-tax profit coming from other income.
Price around the results
Revenue growth remained ahead of profit growth drivers
Inventurus Knowledge Solutions reported consolidated revenue growth of 20.74% year on year in Q1FY27, with operating profit increasing 24.05%. The 0.88 percentage-point improvement in operating margin reflects expenses growing 19.18%, below the pace of revenue growth. On a sequential basis, however, revenue growth slowed to 4.20% and operating profit declined 1.76%.
Sequential cost pressure reversed the margin trend
Expenses increased 7.40% sequentially, faster than the 4.20% rise in revenue, cutting operating margin by 2.01 percentage points. The margin had improved from 31.24% in Q4FY25 to 35.01% in Q4FY26, so Q1FY27 marks a break in that improvement after three consecutive quarters of expansion. Lower interest expense, down 20.27% sequentially and 44.08% year on year, supported pre-tax profit.
Profit quality was operational, not other-income led
Other income contributed only 0.16% of pre-tax profit, so reported earnings were not materially supported by non-operating income. The sequential tax rate rose 4.22 percentage points to 22.80%, which constrained net profit even as interest costs fell. Year on year, the tax rate was broadly stable, rising 0.56 percentage points.
IKS remains above the reported IT peer median
IKS's 33.00% operating margin was 14.85 percentage points above the 18.15% median for the 29 Information Technology peers that had reported the same quarter. The company said an existing client, Advocate Health, is expanding its revenue-cycle-management partnership across acute and ambulatory operations. Management also said IKS won a California health-system partnership for clinical data migration.
No immediate market reaction; prior moves were mixed
The results were filed after market close, so there was no immediate share-price reaction in the reported period. Across the six previous result reactions, the stock rose four times and fell twice, with a median absolute move of 2.63%. Management's presentation also outlined a FY30 revenue outlook of INR 30,000 million and EBITDA of INR 11,485 million, while targeting sustained EBITDA expansion without significant equity dilution.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 | Q4FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹894 cr | ₹858 cr | +4.20% | +20.74% |
| Other income | ₹0 cr | ₹-1 cr | — | -87.14% |
| Expenses | ₹599 cr | ₹557 cr | +7.40% | +19.18% |
| Operating profit | ₹295 cr | ₹300 cr | -1.76% | +24.05% |
| Operating margin (%) | 33.00% | 35.01% | — | — |
| Interest | ₹10 cr | ₹13 cr | -20.27% | -44.08% |
| Depreciation | ₹34 cr | ₹34 cr | +0.68% | +22.90% |
| Profit before tax | ₹251 cr | ₹253 cr | -0.80% | +28.77% |
| Tax | ₹57 cr | ₹47 cr | +21.73% | +31.98% |
| Net profit | ₹194 cr | ₹206 cr | -5.94% | +27.85% |
| EPS (₹) | ₹11.55 | ₹12.31 | -6.17% | +27.34% |
Operating margin of 33.00% compares with a Information Technology sector median of 18.15% across 29 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- The FY30 outlook chart shows revenue of INR 30,000 million and EBITDA of INR 11,485 million.
- The medium-term outlook targets sustained EBITDA expansion without significant equity dilution.
- The outlook chart lists net debt of INR 3,000 million for FY30.
New orders
- IKS won a strategic partnership with a premier California health system for clinical data migration for an acquired hospital.
- Existing client Advocate Health is significantly expanding its RCM partnership, including coding, across its acute and ambulatory network.
Problems & risks
- ROE declined due to a higher equity base from Abridge revaluation and lower earnings from reduced currency gains and acquisition costs.
What to watch
- Whether operating margin recovers from 33.00% after the 2.01-point sequential decline.
- Whether expense growth remains below revenue growth after the 7.40% versus 4.20% sequential gap.
- Whether the tax rate moves back from 22.80% toward the 18.58% reported in Q4FY26.